Research & Education

ELCC 2016: Patients with EGFR expressing non-small-cell lung cancer benefit most from necitumumab added to chemotherapy

GENEVA, Switzerland, 15 April 2016 – Patients with epidermal growth factor receptor (EGFR) expressing advanced squamous non-small-cell lung cancer benefit most from necitumumab added to gemcitabine and cisplatin chemotherapy, according to a subgroup analysis from the SQUIRE trial presented today at the European Lung Cancer Conference (ELCC) 2016 in Geneva, Switzerland.

ELCC 2016: Studies confirm benefit of plasma genotyping to predict treatment benefit in patients with non-small-cell lung cancer

GENEVA, Switzerland, 15 April 2016 – The benefit of plasma genotyping to predict treatment benefit in patients with non-small-cell lung cancer (NSCLC) is confirmed in three studies presented today at the European Lung Cancer Conference (ELCC) 2016 in Geneva, Switzerland.1 Researchers however warned that plasma tests are unlikely to fully replace tissue biopsies.

ELCC 2016: Immunotherapy with live bacterium improves response rate in malignant pleural mesothelioma

GENEVA, Switzerland, 14 April 2016 – Immunotherapy with a live bacterium combined with chemotherapy demonstrated more than 90% disease control and 59% response rate in patients with malignant pleural mesothelioma (MPM), according to the results of a phase Ib trial presented today at the European Lung Cancer Conference (ELCC) 2016 in Geneva, Switzerland.

ELCC 2016: Osimertinib given as first-line treatment may alter biology of EGFR mutated non-small-cell lung cancer

GENEVA, Switzerland, 14 April 2016 – The third generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) osimertinib is effective in the first-line treatment of EGFR mutated non-small- cell lung cancer (NSCLC), according to a late-breaking abstract presented at the European Lung Cancer Conference (ELCC) 2016 in Geneva, Switzerland.1 A second late-breaking abstract confirms the drug’s effectiveness in patients with the T790M mutation.

A Novel Mechanism of Crizotinib Resistance in a ROS1+ NSCLC Patient

DENVER – Molecular analysis of a tumor biopsy from a proto-oncogene 1 receptor tyrosine kinase positive (ROS1+) patient with acquired crizotinib resistance revealed a novel mutation in the v-kit Hardy Zuckerman 4 feline sarcoma viral oncogene homolog receptor tyrosine kinase (KIT) that can potentially be targeted by KIT inhibitors.

Trained Technicians Using CV Software Improved the Accuracy and Quality of LDCT Scans

DENVER – Trained technician screeners with assisted computer-aided nodule detection or computer vision (CV) screening workstations can efficiently and accurately review and triage abnormal low-dose computed topography (LDCT) scans for radiologist review.

Pages